At Novartis, we are reimagining medicine
Novartis and Microsoft announce AI collaboration
Novartis and Microsoft announce collaboration to transform medicine with artificial intelligenceOpens a Dialog
Word on the Street: What is cell and gene therapy?
We leave the lab to find out what people know about cell and gene therapy and what makes these treatment approaches different.
Women in Science: Lauren Abrey
Learn about the career of our Global Medical Affairs Head for Solid Tumors and Rare Diseases.
- Oct 16, 2019
Novartis announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase III study of acute graft-versus-host disease
- Oct 10, 2019
Novartis data show Cosentyx® treatment results in rapid and sustained resolution of signs and symptoms of psoriatic arthritis in patients with and without enthesitis
- Oct 09, 2019
Novartis real-world evidence confirms high efficacy, long-term response and favorable safety profile of Cosentyx® in clinical practice
- Oct 08, 2019
Novartis data show more patients are completely symptom-free from chronic spontaneous urticaria with ligelizumab (QGE031) than Xolair® 300 mg
We are proud to sponsor #UNDiningInTheDark and to join forces with #GCOA in taking action against vision impairment… https://t.co/FSiupDGYWh@Novartis 1 week 1 day ago
Congratulations to @zipline for increasing access to critical medical supplies by opening a second airborne distrib… https://t.co/XyT45HUDlf@Novartis 1 week 2 days ago
On this #WorldSightDay, envision a future where we can all see the world through the wonder of our eyes. https://t.co/sD2iPBOYLy
This site is intended for a global audience.